Our results indicate that thymic BCL11b-low T-ALL patients represent a high risk subgroup which would benefit from intensified MRD monitoring and treatment stratification including allogeneic stem cell transplantation. The gene discussed is BCL11B; the disease is acute lymphoblastic leukemia.